Edoxaban treatment in atrial fibrillation in routine clinical care: One-year outcomes of the prospective observational ETNA-AF study in South Korean patients.
Eue-Keun ChoiJong-Il ChoiHyoung Seob ParkGyo-Seung HwangBoyoung JoungJong-Youn KimDae-Hyeok KimDong Gu ShinHyung Wook ParkPublished in: Journal of arrhythmia (2023)
The outcomes in the Korean ETNA-AF population are like those in the global ETNA-AF population, with overall low event rates of stroke, major bleeding and all-cause mortality across age and dose subgroups. Edoxaban can be used effectively and safely in specific populations of Korean AF patients, including the elderly.
Keyphrases
- atrial fibrillation
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- healthcare
- catheter ablation
- oral anticoagulants
- direct oral anticoagulants
- venous thromboembolism
- percutaneous coronary intervention
- patient reported outcomes
- coronary artery disease
- acute coronary syndrome
- weight loss
- skeletal muscle
- patient reported
- health insurance
- left ventricular
- smoking cessation